



(51) International Patent Classification:

A61K 39/00 (2006.01) A61K 9/00 (2006.01)
A61K 39/12 (2006.01) A61K 9/127 (2006.01)

(21) International Application Number:

PCT/US2013/045578

(22) International Filing Date:

13 June 2013 (13.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/660,172 15 June 2012 (15.06.2012) US

(71) Applicant: PDS BIOTECHNOLOGY CORPORATION [US/US]; 500 Industrial Drive, Suite A, Lawrenceburg, Indiana 47025 (US).

(72) Inventors; and

(71) Applicants : MKRTICHYAN, Mikayel [AM/US]; 14201 Arbor Forest Drive, Apt. 201, Rockville, Maryland 20850 (US). KHLEIF, Samir N. [US/US]; 13408 Hathaway Drive, Silver Spring, Maryland 20906 (US).

(72) Inventors: JOHNSON, Kenya; 3411 Pinnacle Lane, Mason, Ohio 45040 (US). JACOBSON, Eric; 5785 Charter Oak Drive, Cincinnati, Ohio 45236 (US). BEDU-ADDO, Frank; 3 Penny Lane, Bethel, Connecticut 06801 (US).

(74) Agents: ADDISON, Bradford G. et al.; Barnes & Thornburg LLP, 11 South Meridian Street, Indianapolis, Indiana 46204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE




Figure 1

(57) Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.

WO 2013/188627 A3



- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

6 February 2014

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 13/45578

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - A61K 39/00, A61K 39/12, A61K 9/00, A61K 9/127 (2013.01)
 USPC - 424/184.1, 424/400
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC(8): A61K 39/00, A61K 39/12, A61K 9/00, A61K 9/127 (2013.01);
 USPC: 424/184.1, 424/400

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 USPC: 424/185.1, 424/204.1, 424/277.1, 424/450

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 PubWEST, PatBase, Google Patents, Google Scholar: Vaccine, adjuvant, cationic lipid, DOTAP, DOTMA, DOEPC, enantomer, R-DOTAP, RDOTAP, therapeutic factor, cytokine, GM-CSF, antigens, HPV, protein, peptide, human papilloma virus, human papillomavirus, pp100, TRP2, CD8, T cell, T-cell, MDSC, myeloid-derived suppressor cells

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2011/0110972 A1 (VASIEVICH et al.) 12 May 2011 (12.05.2011); para [0033], [0040], [0064], [0068], [0091], [0100]	1-5, 7-8, 20-26, 28-29 ----- 6, 9, 14-15, 27, 30
X --- Y	US 2008/0152665 A1 (LECLERC et al.) 26 June 2008 (26.06.2008); abstract, para [0019], [0021], [0035], [0036], [0070], [0095], [0194], [0195]	10-13, 17-18 ----- 14-16, 19
Y	US 2012/0148622 A1 (TENOEVER) 14 June 2012 (14.06.2012); para [0103]	6, 16, 27
Y	US 2011/0305713 A1 (MUNN et al) 15 December 2011 (15.12.2011); SEQ ID NO: 2; para [0038].	9, 19, 30
A	EMBL database entry GG774706, Bacteroides sp. 1_1_14 genomic scaffold supercont1.5, 2010-06-15, [retrieved on 2013-10-28], Retrieved from the Internet: <URL: http://www.ebi.ac.uk/ena/data/view/GG774706&display=text>	9, 19, 30

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 29 October 2013 (29.10.2013)	Date of mailing of the international search report 25 NOV 2013
---	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774
---	---